Quantcast
Last updated on April 20, 2014 at 17:20 EDT

International Research Teams Confirm Patented Gymnema Sylvestre Extract Reduces Blood Glucose In Vitro and In Vivo Clinicals

July 21, 2010

NEENAH, Wis., July 21 /PRNewswire/ — A scientific journal, Phytotherapy Research (May 17, 2010), has reported findings from research teams at King’s College London and at Burdwan Medical College, J. B. Ayurved College and Calcutta University (West Bengal). The conclusions confirm the earlier findings of Ayurvedic-Life that the patented Gymnema sylvestre extract, OSA(TM) (Om Santal Adivasi), stimulated insulin secretion from human islets in vitro and in vivo. They also confirmed earlier reported findings that OSA(TM) is not associated with pancreatic beta cell damage. This scientific study reasserts the positive effects of the multi-patented OSA(TM) technology.

For this sixty day in vivo study, the patients–following the Helsinki protocol–consented to testing on the effects of OSA(TM) administration on blood glucose and insulin levels in the human body. C-Peptide levels were also measured as part of the research. A dosage of two 250mg capsules of OSA(TM) was administered orally, twice per day, prior to food intake.

The results of this analysis show that study participants experienced significant reductions in both fasting and post-prandial blood glucose levels. In addition, improvements in glycemic control were associated with significant increased circulating levels of insulin and C-Peptide. Throughout the course of the study, the body weight of the participants remained unchanged.

The effect of OSA(TM) on the pattern and rate of insulin secretion in vitro was further examined by using isolated human pancreatic islets of Langerhans (the regions of the pancreas that contain endocrine cells, which produce hormones). The response to OSA(TM) was rapid in onset, was sustained for the duration of exposure to OSA(TM) and reversed once it was withdrawn.

Ayurvedic-Life International Chairman and CEO and OSA(TM) inventor, Dr. Arun K. Chatterji commented on the findings, saying: “Our patented OSA(TM) Gymnema sylvestre extract has proven to be an exceptional addition to the stable of phytotherapies available to help millions of people with their health issues. We are very pleased that the research teams in London and India brought their world class expertise to bear on this project.”

Ayurvedic-Life International, LLC, a Wisconsin-based biotechnology company, applies the results of its proprietary studies to developing products that utilize the science of Ayurvedic medicine.

For more information please visit www.ayurvedic-life.com.

SOURCE Ayurvedic-Life International, LLC


Source: newswire